Risk Assessment

My posts are often positive and with forward looking possibilities but that does not mean that I do not see the risks so I have decided to share these with you and perhaps you can add to them or reassess them.
Perhaps the one which keeps me awake the most is the fifth on that list. I still do not understand how the company was able to report a $50M contribution in FY22 (Scott Richards) and turn that into a -$17M loss in the first half of 23 (Shaun O'Brien). The company explained it thus:

●Poor result, as flagged at AGM, attributable to the long winddown of channel inventories built in June 22 to launch new products / gainmarket share
●1HFY23categorised by competitive price pressure, one off GTN impacts on key products as well as other one time adjustments
●Methodology change on estimating CoPay accrual addresses timing issues on earnings recognition

If someone can explain what this is and how it came about, I'd be grateful.

Risk Assessment
Possible Event	Probability	Consequence
Legislation changes leading to either higher competition or lower prices	Low	V High
WH product sales either plateau or slow down this year	L to M	Medium
DTC Dermatology is copied by competitor	Low	High
Large Product litigation	Low	V High
Dermatology channel issues as per 1HFY23	Medium	High
Pressure on capital due to legacy issues (previous businesses)	M to H	Low
Hostile takeover	Low	Medium
Asset Impairments (as per last 7 years)	Low	V High
Purchase of new products not already on market	Low	Medium
Expansion of WH into other areas eg Oncology	M	Low
Shareholder class action	V High	V Low
Future Dividends paid next year	Low	Low
Large purchase of business or products leading to high debt or capital raising	Low	Medium
IPO in the US before company is profitable	Low	Medium